Epileptic spasms …

Hiroki Nariai MD PhD MS

Epilepsy & Seizures

Updated 09.06.2024
Released 09.08.2003
Expires For CME 09.06.2027

Epileptic spasms

Author: Hiroki Nariai MD PhD MS

See Contributor Disclosures

Editor: Solomon L Moshé MD

Epileptic spasms

In This Article

Quick Link

Introduction

Overview

Epileptic spasms are a peculiar seizure-type that usually manifest in infants as infantile epileptic spasms syndrome (IESS), including West syndrome. These seizures characteristically occur in daily clusters upon awakening, and individual spasms typically manifest with a brief axial contraction (ie, head-drop), with simultaneous flexion or extension of the arms, and intermixed limbic phenomena, such as fear and crying. Epileptic spasms are often accompanied by severely abnormal interictal epileptiform patterns, such as hypsarrhythmia, and they demand prompt diagnosis and treatment given the potential for enduring intellectual harm as a result of inadequate or late treatment. The author details contemporary treatment protocols.

Key points

	• Video-EEG is critical to confirm epileptic spasms and distinguish it from mimics.
	• Prompt diagnosis of epileptic spasms is essential as delays in treatment are associated with treatment failure and diminished long-term neurodevelopmental outcomes.
	• Epileptic spasms may be exacerbated by traditional antiseizure drugs that target voltage-gated sodium channels (eg, carbamazepine, oxcarbazepine).

Historical note and terminology

Having observed epileptic spasms in his own son, Dr. William West first provided a terrifying account of the phenomena in an 1841 letter to the editor of The Lancet (42). Accordingly, West syndrome has come to denote the triad of epileptic spasms, intellectual impairment, and hypsarrhythmia—the classic interictal electroencephalography (EEG) pattern often accompanying epileptic spasms (15). As it pertains to epileptic spasms, nomenclature continues to be a challenge. A great variety of terms have been used to describe epileptic spasms, including salaam convulsions, komplimentierkrämpfe, spasmes salutatoires, lightning major seizures, startle seizures, and others (35). The conceptualization of West syndrome is problematic because a principle goal of care is the prevention of intellectual disability, and epileptic spasms often occur without hypsarrhythmia. Furthermore, although the most popular contemporary descriptor is infantile spasms, “epileptic spasms” is the favored descriptor because this seizure type can be present in infants, as well as in older children, and, occasionally, in adults (03). The International League Against Epilepsy (ILAE) developed the terminology of infantile epileptic spasms syndrome (IESS) to encompass both West syndrome as well as infants presenting with epileptic spasms who do not fulfill all the criteria for West syndrome (46).

Clinical manifestations

Presentation and course

Epileptic spasms (hereafter, spasms) consist of brief contractions of the axial musculature that may be in flexion, extension, or a combination thereof, typically accompanied by a concomitant extension of the upper extremities, and often brief but prominent opening of the eyes (35; 44). Individual spasms last a fraction of a second (usually 0.5 to 1.0 second) but characteristically recur in clusters, with repetitions approximately every 5 to 45 seconds, with individual clusters usually lasting several minutes and rarely more than 1 hour (30). Clusters are most frequent upon awakening in the morning but may occur at any time of day, and multiple clusters in a single day are not uncommon. There is great heterogeneity in semiology, and spasms may be symmetric or asymmetric, with lateral deviation of the eyes or head, or involving only 1 side of the body. Individual spasms are often followed by brief (ie, 5 to 10 seconds) spells of crying, which may reflect emotional and limbic phenomena; we have observed several cases in older children who report feelings of tremendous fear intermixed in a cluster of spasms. In many cases, spasms may be extraordinarily subtle with only minimal axial or appendicular movement, and perhaps only a modest but stereotyped change in facial expression or eye opening. Identification can be exceptionally challenging in these subtle cases, especially for the practitioner who has not actually seen the events and must depend on caregiver report. Diagnosis and treatment are often substantially delayed and inadequate awareness of spasms is at least partly responsible for preventable and potentially significant delays (19). The contemporary use of video documentation by parents has greatly aided identification.

The onset of spasms is before 1 year of age in the vast majority of cases, with peak incidence between 3 and 7 months (30). However, spasms may begin at birth, or they may appear long after the age of 12 months (33), with rare reports of incidence in adolescence (01). In cases with prompt identification and successful treatment, intellectual and epilepsy-related outcomes can be excellent (24; 10). However, given the challenges of identification, potential delays in effective treatment, and frequent underlying causes of spasms that are associated with poor intellectual outcomes independent of seizures (eg, trisomy 21), intellectual outcomes are often poor (35; 29).

Prognosis and complications

The outcome of spasms is generally poor but highly variable (38; 10). Key factors include whether or not treatment is prompt and successful, and whether identified causes of spasms are associated with poor epilepsy and developmental outcomes regardless of the presence or absence of spasms (eg, nonketotic hyperglycinemia) (29). In cases in which there is no developmental impairment prior to the onset of spasms and no identifiable cause of spasms despite a thorough work-up (classically termed cryptogenic), outcomes may be excellent (normal intellect and seizure freedom) with prompt and successful therapy.

Clinical vignette

For the past 4 weeks, a 7-month-old boy has had stereotyped episodes manifesting with a sudden extension of the neck and tonic stiffening of the bilateral upper extremities, occurring in clusters each morning. Gastroesophageal reflux was initially suspected, but empiric treatment with an antihistamine, and subsequently, proton-pump inhibitor was unsuccessful. Since the onset of the episodes, the boy has not been able to sit independently and has seemed less interactive. The developmental regression prompted neurologic consultation, which led to video EEG monitoring that then demonstrated epileptic spasms. On physical exam, several hypopigmented ellipsoid macules were seen on the trunk and extremities. MRI brain demonstrated subependymal nodules and scattered cortical tubers. A presumptive clinical diagnosis of tuberous sclerosis complex was later confirmed by genetic testing.

Biological basis

Localization

The localization of spasms is highly varied, and they may appear focal or generalized from the standpoint of clinical semiology, as well as ictal electroencephalography. Indeed, we have observed many cases due to focal cortical dysplasia (FCD), with sustained seizure freedom following resection of cortical dysplasia, in which no clues of focality could be discerned from semiology on video review or ictal electrographic signature. In these cases, focality was established with MRI, interictal positron emission tomography (PET) (09), and interictal intraoperative electrocorticography. In cases of focal and generalized origin, widespread cortical dysfunction is often demonstrated by (1) hypsarrhythmia and related patterns on interictal EEG, (2) widespread cortical hypometabolism on interictal brain PET, and (3) often simultaneous relative hypermetabolism in the caudate nuclei and other deep brain structures (08; 07). Moreover, this widespread cortical dysfunction, even in the face of focal sources of spasms, is thought to be responsible for the cognitive and developmental regression that frequently accompanies the early progression of spasms.

Pathophysiology

A precise pathophysiologic characterization of spasms has proven elusive. Though great progress has been made in the last decade, a new crop of animal models leave much to be desired as they do not adequately mirror the phenomena in humans; no single model based on a known cause of spasms in humans has been shown to exhibit spasms with ictal electrodecremental response, hypsarrhythmia, enduring unprovoked seizures, analogous neurodevelopmental sequelae, and responsiveness to the therapies that have been proven effective in humans (14). It is perplexing that so many disparate structural, metabolic, and genetic disorders have been associated with spasms, and yet among patients with these disorders, those manifesting comorbid spasms represent a small minority. The presumably genetic factors that distinguish patients at risk for spasms from those who actually manifest spasms are unknown. Such a discovery could facilitate the design of an ideal animal model and ultimately lead to superior therapies.

Differential diagnosis

Confusing conditions

The identification of spasms from clinical observation alone can be exceptionally challenging (27). Accurate diagnosis requires both ictal and interictal video-EEG monitoring (30). The most common mimics of spasms include Sandifer syndrome, fairly stereotyped axial contortions associated with infantile gastroesophageal reflux, myoclonic seizures and sleep myoclonus, brief tonic seizures, and a wide array of rapid stereotyped behaviors that are normally, if not commonly, observed in healthy infants. Rapid and correct differential diagnosis of suspicious events is essential as treatments for the above entities are radically different than spasms, and the neurodevelopmental cost of incorrect diagnosis and delayed treatment can be enormous.

Associated and underlying disorders

Spasms are a key element of West syndrome (the triad of spasms, hypsarrhythmia, and intellectual disability) and Ohtahara syndrome (early infantile epileptic encephalopathy), and they occasionally persist in children who develop Lennox-Gastaut syndrome. More generally, spasms occur as a consequence of myriad diseases and syndromes that affect the central nervous system in infancy. Although spasms may commence in older children and adults, spasms are highly age-specific with the vast majority of cases presenting in infancy and resolving by the 2 to 4 years of age. As it pertains to etiology, spasms are highly nonspecific. The most common associations with spasms include focal cortical dysplasia, hypoxic ischemic encephalopathy, tuberous sclerosis complex, stroke, intracranial hemorrhage, hemimegalencephaly, lissencephaly, polymicrogyria, trisomy 21, Aicardi syndrome, nonketotic hyperglycinemia, Menke disease, neurofibromatosis type 1, mutations of the ARX, CDKL5, and ASTXBP1 genes, and deletions and duplications of the chromosome 15q locus. Contemporary associations with numerous other gene defects are rapidly being identified with the expanded use of whole exome and whole genome sequencing algorithms.

Diagnostic workup

The cornerstone of diagnosis is video-EEG characterization of both events as well as the interictal background. Ictal EEG allows the distinction of spasms from normal behaviors and other types of seizures, and EEG characterization of sleep permits an adequate characterization of interictal patterns associated with spasms, namely hypsarrhythmia and related patterns. Hypsarrhythmia—the interictal phenomena defined by exceptionally high voltage (non-epileptiform slow-waves greater than 200 µV), disorganization, and multifocal epileptiform discharges (15; 18)—is thought to be a key marker for both the widespread cortical dysfunction neurodevelopmental sequelae, but its identification can be rather challenging (22).

Once spasms are confirmed, a search for the underlying etiology of spasms is critical, as this may impact the choice of initial therapy. Informed by clinical history, typical diagnostic approaches usually begin with brain MRI to identify structural causes of spasms (eg, focal cortical dysplasia, cortical tubers, hemimegalencephaly, neoplasms, stroke, and other vascular phenomena). In cases without identified structural abnormalities, the diagnostic approach then focuses on a search for genetic and metabolic entities such as Down syndrome, nonketotic hyperglycinemia, pyridoxine deficiency, and countless others. Contemporary approaches to genetic testing include targeted gene testing in cases in which a specific genetic disorder is suspected. In cases with high pretest suspicion of a genetic cause, but low pretest suspicion of a specific gene defect, contemporary approaches typically include chromosomal microarray analysis, epilepsy gene panels, and whole exome/genome sequencing (45).

Management

Spasms are often refractory to traditional antiseizure drugs and may be exacerbated by agents that inhibit voltage-gated sodium channel currents (eg, carbamazepine, oxcarbazepine) (39). Among commonly prescribed antiseizure drugs, topiramate (16; 41), zonisamide (37), and valproate (06), appear to exhibit only modest efficacy.

The most favorable response rates have been reported with the use of hormonal therapies including natural and synthetic adrenal corticotropic hormone (ACTH) (02) and corticosteroids including prednisolone (21). However, these therapies are associated with myriad side effects—the most important of which include immunosuppression, hypertension, and hyperglycemia. Although there is debate as to the ideal agent and dosage of hormonal therapies, and few head-to-head comparisons of competing regimens, high-dose protocols seem to confer additional benefit. At our center, we advocate for high-dose prednisolone (8 mg/kg/day, max 60 mg/day, divided in 3 daily doses) and high-dose ACTH (150 IU/m2 body surface area/day, divided in twice daily intramuscular injections) (21).

Vigabatrin is considered first-line treatment at many centers, especially for patients with tuberous sclerosis complex (40). Like hormonal therapy, the highest response rates have accompanied the use of relatively high dosage (100 to 150 mg/kg/day divided in 2 daily doses) (12). The use of vigabatrin is limited by fears of irreversible peripheral vision loss (11) as well as rare but potentially fatal phenomena associated with subcortical MRI signal changes (17). However, some of these fears may be overstated. At least with respect to vision loss, the incidence of visual field constriction (32) and electroretinographically-defined retinotoxicity (43) appear to be low with short courses of vigabatrin, and the prevalence of clinically-apparent vision loss is nearly zero (34).

Of note, a randomized controlled trial demonstrated that the combination of vigabatrin and hormonal therapy (high dose prednisolone or synthetic ACTH) resulted in higher short-term response rates and more rapid resolution of spasms (28), and early clinical response to treatment was associated with improved developmental and epilepsy outcomes at 18 months (28).

Though supportive data are less compelling, a variety of nonpharmacologic therapies have been advocated for use in treatment of spasms, including ketogenic diet therapy (25; 20) and vagal nerve stimulation (05).

Among contemporary developments, great fanfare has accompanied the use of artisanal cannabis extracts in the treatment of several severe forms of childhood epilepsy, including epileptic spasms (22). Several randomized controlled trials have been evaluating cannabidiol's efficacy, safety, and tolerability (NCT02953548; NCT03421496). Given the relatively fast progression of cognitive impairment that typically accompanies spasms and hypsarrhythmia, treatment is a relative emergency and should ideally begin within days of spasms onset and immediately on diagnostic confirmation. Similarly, response to a given therapy must be accomplished quickly and confirmed with extended video-EEG to ensure that neither hypsarrhythmia nor subtle spasms continue. Most contemporary treatment protocols require response within 2 weeks and immediately transition nonresponders to alternative agents. As an example, the Canadian Pediatric Epilepsy Network has demonstrated success with a protocol that begins with vigabatrin, with nonresponders transitioning to synthetic ACTH at the 2-week time point, and then transitioning patients who fail both vigabatrin and ACTH to topiramate at the 4-week time point (04). There are no adequate guides to therapy for patients who have failed first-line agents.

Outcomes

The long-term outcome of spasms is highly variable with respect to both epilepsy outcomes and neurodevelopmental outcomes. In considering infants (ie, IESS, including West syndrome), a significant minority become seizure-free and developmentally normal by age 2 years (13). However, mortality rates are markedly elevated throughout life and the leading causes of death are pneumonia among infants and sudden unexpected death in epilepsy (SUDEP) in adults (36). Most survivors who do not attain seizure freedom by age 2 years transition to other forms of epilepsy (eg, Lennox-Gastaut syndrome) and exhibit developmental impairment.

References

01: Auvin S, Lamblin MD, Pandit F, Vallée L, Bouvet-Mourcia A. Infantile epileptic encephalopathy with late-onset spasms: report of 19 patients. Epilepsia 2010;51(7):1290-6. PMID 20345938
02: Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics 1996;97(3):375-9. PMID 8604274
03: Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 2010;51(4):676-85. PMID 20196795
04: Bitton JY, Sauerwein HC, Weiss SK, et al. A randomized controlled trial of flunarizine as add-on therapy and effect on cognitive outcome in children with infantile spasms. Epilepsia 2012;53(9):1570-6. PMID 22889307
05: Cersósimo RO, Bartuluchi M, Fortini S, Soraru A, Pomata H, Caraballo RH. Vagus nerve stimulation: effectiveness and tolerability in 64 paediatric patients with refractory epilepsies. Epileptic Disord 2011;13(4):382-8. PMID 22258042
06: Chandra S, Bhave A, Bhargava R, Kumar C, Kumar R. West syndrome: response to valproate. Front Neurol 2012;3:166. PMID 23189070
07: Chugani HT, Da Silva E, Chugani DC. Infantile spasms: III. Prognostic implications of bitemporal hypometabolism on positron emission tomography. Ann Neurol 1996;39(5):643-9. PMID 8619550
08: Chugani HT, Shewmon DA, Sankar R, Chen BC, Phelps ME. Infantile spasms: II. Lenticular nuclei and brain stem activation on positron emission tomography. Ann Neurol 1992;31(2):212-9. PMID 1575460
09: Chugani HT, Shields WD, Shewmon DA, Olson DM, Phelps ME, Peacock WJ. Infantile spasms: I. PET identifies focal cortical dysgenesis in cryptogenic cases for surgical treatment. Ann Neurol 1990;27(4):406-13. PMID 2353794
10: Darke K, Edwards SW, Hancock E, et al. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch Dis Child 2010;95(5):382-6. PMID 20457702
11: Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314(7075):180-1. PMID 9022432
12: Elterman RD, Shields WD, Bittman RM, Torri SA, Sagar SM, Collins SD. Vigabatrin for the treatment of infantile spasms: final report of a randomized trial. J Child Neurol 2010;25(11):1340-7. PMID 20404353
13: Gaily E, Lommi M, Lapatto R, Lehesjoki AE. Incidence and outcome of epilepsy syndromes with onset in the first year of life: a retrospective population-based study. Epilepsia 2016;57(10):1594-1601. PMID 27574005
14: Galanopoulou AS 2013. Basic mechanisms of catastrophic epilepsy – overview from animal models. Brain Dev 2013;35(8):748-56.
15: Gibbs FA, Gibbs EL. Infantile Spasms. In: Atlas of Electroencephalography, Vol 2. Reading, MA: Addison-Wesley, 1952:24-30.
16: Glauser TA, Clark PO, McGee K. Long-term response to topiramate in patients with West syndrome. Epilepsia 2000;41 Suppl 1:S91-4. PMID 10768309
17: Hernández Vega Y, Kaliakatsos M, U-King-Im J, Lascelles K, Lim M. Reversible vigabatrin-induced life-threatening encephalopathy. JAMA Neurol 2014;71(1):108-9. PMID 24247994
18: Hrachovy RA, Frost JD Jr, Kellaway P. Hypsarrhythmia: variations on the theme. Epilepsia 1984;25(3):317-25. PMID 6539199
19: Hussain SA, Lay J, Cheng E, et al. Recognition of infantile spasms is often delayed: the ASSIST study. J Pediatr 2017;190:215-21. PMID 29144248
20: Hussain SA, Shin JH, Shih EJ, et al. Limited efficacy of the ketogenic diet in the treatment of highly refractory epileptic spasms. Seizure 2016;35:59–64. PMID 26803052
21: Hussain SA, Shinnar S, Kwong G, et al. Treatment of infantile spasms with very high dose prednisolone before high dose adrenocorticotropic hormone. Epilepsia 2014;55(1):103-7. PMID 24446954
22: Hussain SA, Zhou R, Jacobson C, et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav 2015;47:138-41. PMID 25935511
23: Jozwiak S, Kotulska K, Domańska-Pakieła D, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol 2011;15(5):424-31. PMID 21507691
24: Kivity S, Lerman P, Ariel R, Danziger Y, Mimouni M, Shinnar S. Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia 2004;45(3):355-62. PMID 15009227
25: Kossoff EH, Pyzik PL, McGrogan JR, Vining EPG, Freeman JM. Efficacy of the ketogenic diet for infantile spasms. Pediatrics 2002;109(5):780-3. PMID 11986436
26: Kotulska K, Kwiatkowski DJ, Curatolo P, et al. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann Neurol 2021;89(2):304-14.** PMID 33180985
27: Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group. Epilepsia 2004;45(11):1416-28. PMID 15509243
28: O'Callaghan FJ, Edwards SW, Alber FD, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol 2017;16(1):33-42. PMID 27838190
29: O’Callaghan FJ, Lux AL, Darke K, et al. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. Epilepsia 2011;52(7):1359-64. PMID 21668442
30: Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a U.S. consensus report. Epilepsia 2010;51(10):2175-89. PMID 20608959
31: Riikonen R. Epidemiological data of West syndrome in Finland. Brain Dev 2001;23(7):539-41. PMID 11701251
32: Riikonen R, Rener-Primec Z, Carmant L, et al. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study. Dev Med Child Neurol 2015;57(1):60-7. PMID 25145415
33: Ronzano N, Valvo G, Ferrari AR, Guerrini R, Sicca F. Late-onset epileptic spasms: clinical evidence and outcome in 34 patients. J Child Neurol 2015;30(2):153-9. PMID 24907139
34: Schwarz MD, Li M, Tsao J, et al. A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience. Epilepsy Behav 2016;57(Part A):29-33. PMID 26921595
35: Shields WD. Infantile spasms: little seizures, BIG consequences. Epilepsy Curr 2006;6(3):63-9. PMID 16761063
36: Sillanpää M, Riikonen R, Saarinen MM, Schmidt D. Long-term mortality of patients with West syndrome. Epilepsia Open 2016;1(1-2):61-6. PMID 29588929
37: Suzuki Y, Imai K, Toribe Y, et al. Long-term response to zonisamide in patients with West syndrome. Neurology 2002;58(10):1556-9. PMID 12034801
38: Trevathan E, Murphy CC, Yeargin-Allsopp M. The descriptive epidemiology of infantile spasms among Atlanta children. Epilepsia 1999;40(6):748-51. PMID 10368073
39: Veerapandiyan A, Singh P, Mikati MA. Possible induction of West syndrome by oxcarbazepine therapy in a patient with complex partial seizures. Epileptic Disord 2012;14(1):99-103. PMID 22425652
40: Vigevano F, Arzimanoglou A, Plouin P, Specchio N. Therapeutic approach to epileptic encephalopathies. Epilepsia 2013;54 Suppl 8:45-50. PMID 24571117
41: Weber A, Cole JW, Mytinger JR. Infantile spasms respond poorly to topiramate. Pediatr Neurol 2015;53(2):130-4. PMID 26068002
42: West WJ. On a peculiar form of infantile convulsions. Lancet 1894;1:724-5.
43: Westall CA, Wright T, Cortese F, Kumarappah A, Snead OC 3rd, Buncic JR. Vigabatrin retinal toxicity in children with infantile spasms: an observational cohort study. Neurology 2014;83(24):2262-8. PMID 25381295
44: Wheless JW, Gibson PA, Rosbeck KL, et al. Infantile spasms (West syndrome): update and resources for pediatricians and providers to share with parents. BMC Pediatr 2012;12:108. PMID 22830456
45: Wirrell EC, Shellhaas RA, Joshi C, et al. How should children with West syndrome be efficiently and accurately investigated? Results from the National Infantile Spasms Consortium. Epilepsia 2015;56(4):617-25. PMID 25779538
46: Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1349-97. PMID 35503712

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Hiroki Nariai MD PhD MS

Dr. Nariai of the David Geffen School of Medicine at UCLA has no relevant financial relationships to disclose.
See Profile

Editor

Solomon L Moshé MD

Dr. Moshé of Albert Einstein College of Medicine has no relevant financial relationships to disclose.
See Profile

Former Authors

Shaun Hussain MD MS
Jerome Engel Jr MD PhD
Rima Nabbout MD PhD and Olivier Dulac MD

Patient Profile

Age range of presentation: 0 to 12 years
Sex preponderance: Male > female
Heredity: Heredity may be a factor.
Population groups selectively affected: None
Occupation groups selectively affected: None

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Epileptic spasms

Associated Disorders

Aicardi syndrome
chromosomal deletions
Early myoclonic encephalopathy
Focal cortical dysplasia
gene mutations
- inborn errors of metabolism
- Lennox-Gastaut syndrome
- Menkes disease
- Miller-Dieker syndrome and classic lissencephaly
- Ohtahara syndrome
- Tuberous sclerosis complex
- West syndrome

Differential Diagnosis

benign myoclonic epilepsy in infancy
tonic seizures
Sandifer syndrome (gastroesophogeal reflux)

Also Relevant

Epilepsy
Generalized onset tonic seizures
West syndrome

Clinical Categories

Epilepsy & Seizures

Patient Handouts

Infantile spasms

Web References

Guidelines

Epileptic spasms …

Epileptic spasms

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Localization

Pathophysiology

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated and underlying disorders

Diagnostic workup

Management

Outcomes

References

Contributors

Author

Editor

Former Authors

Patient Profile

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Photosensitive occipital lobe epilepsy

Intermittent explosive disorder

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

Reflex seizures

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

Epileptic spasms

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Localization

Pathophysiology

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated and underlying disorders

Diagnostic workup

Management

Outcomes

References

Contributors

Author

Editor

Former Authors

Patient Profile

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Photosensitive occipital lobe epilepsy

Intermittent explosive disorder

Pyridoxine/P5P-dependent developmental epileptic encephalopathy

Reflex seizures

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

This is an article preview.
Start a Free Account
to access the full version.